Skip Nav Destination
Issues
Perceived Appropriateness of Assessing for Health-related Socioeconomic Risks Among Adult Patients with Cancer
Milkie Vu; Kelly Boyd; Emilia H. De Marchis; Bridgette G. Garnache; Laura M. Gottlieb; Cary P. Gross; Nita K. Lee; Stacy Tessler Lindau; Sophia Mun; Victoria A. Winslow; Jennifer A. Makelarski
Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
Niki Gavrielatou; Ioannis Vathiotis; Thazin Nwe Aung; Saba Shafi; Sneha Burela; Aileen I. Fernandez; Myrto Moutafi; Barbara Burtness; Panagiota Economopoulou; Maria Anastasiou; Periklis Foukas; Amanda Psyrri; David L. Rimm
IOA-244 is a Non–ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance
Zoë Johnson; Chiara Tarantelli; Elisa Civanelli; Luciano Cascione; Filippo Spriano; Amy Fraser; Pritom Shah; Tyzoon Nomanbhoy; Sara Napoli; Andrea Rinaldi; Karolina Niewola-Staszkowska; Michael Lahn; Dominique Perrin; Mathias Wenes; Denis Migliorini; Francesco Bertoni; Lars van der Veen; Giusy Di Conza
RAB27B Drives a Cancer Stem Cell Phenotype in NSCLC Cells Through Enhanced Extracellular Vesicle Secretion
Kayleah M. Meneses; Prita Pandya; Jennifer A. Lindemann; Dania S. Al-Qasrawi; Ryan A. Argo; Celeste M. Weems; Danielle J. Beetler; Geraldine V. Vijay; Irene K. Yan; Joy Wolfram; Tushar Patel; Verline Justilien
African American Prostate Cancer Displays Quantitatively Distinct Vitamin D Receptor Cistrome-transcriptome Relationships Regulated by BAZ1A
Manjunath Siddappa; Shahid Hussain; Sajad A. Wani; Jason White; Hancong Tang; Jaimie S. Gray; Hedieh Jafari; Hsu-Chang Wu; Mark D. Long; Isra Elhussin; Balasubramanyam Karanam; Honghe Wang; Rebecca Morgan; Gary Hardiman; Isaacson B. Adelani; Solomon O. Rotimi; Adam R. Murphy; Larisa Nonn; Melissa B. Davis; Rick A. Kittles; Chanita Hughes Halbert; Lara E. Sucheston-Campbell; Clayton Yates; Moray J. Campbell
Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950
Fumiyoshi Okano; Takanori Saito; Yoshitaka Minamida; Shinichi Kobayashi; Takayoshi Ido; Yasushi Miyauchi; Ukei Wasai; Daisuke Akazawa; Masahiko Kume; Masaki Ishibashi; Ke Jiang; Alexandra Aicher; Christopher Heeschen; Tetsu Yonehara
Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence
Esmee P. Hoefsmit; Franziska Völlmy; Elisa A. Rozeman; Irene L.M. Reijers; Judith M. Versluis; Liesbeth Hoekman; Alexander C.J. van Akkooi; Georgina V. Long; Dirk Schadendorf; Reinhard Dummer; Maarten Altelaar; Christian U. Blank
Whole-genome and Epigenomic Landscapes of Malignant Gastrointestinal Stromal Tumors Harboring KIT Exon 11 557–558 Deletion Mutations
Keiichi Ohshima; Takeshi Nagashima; Keiichi Fujiya; Keiichi Hatakeyama; Yuko Watanabe; Kimiko Morimoto; Fukumi Kamada; Yuji Shimoda; Sumiko Ohnami; Akane Naruoka; Masakuni Serizawa; Shumpei Ohnami; Hirotsugu Kenmotsu; Akio Shiomi; Yasuhiro Tsubosa; Etsuro Bando; Teiichi Sugiura; Takashi Sugino; Masanori Terashima; Katsuhiko Uesaka; Kenichi Urakami; Yasuto Akiyama; Ken Yamaguchi
Mitochondrial Metabolism Drives Low-density Lipoprotein-induced Breast Cancer Cell Migration
Sandrina Nóbrega-Pereira; Francisco Santos; Miguel Oliveira Santos; Teresa L. Serafim; Ana Patrícia Lopes; Diogo Coutinho; Filipa S. Carvalho; Rosário M. Domingues; Pedro Domingues; Bruno Bernardes de Jesus; Vanessa A. Morais; Sérgio Dias
Uncovering the Protective Neurologic Mechanisms of Hypofractionated FLASH Radiotherapy
Yasaman Alaghband; Barrett D. Allen; Eniko A. Kramár; Richard Zhang; Olivia G.G. Drayson; Ning Ru; Benoit Petit; Aymeric Almeida; Ngoc-Lien Doan; Marcelo A. Wood; Janet E. Baulch; Paola Ballesteros-Zebadua; Marie-Catherine Vozenin; Charles L. Limoli
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds